194 related articles for article (PubMed ID: 23184565)
1. Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures.
Barzilay JI; Gao P; Clase CM; Mente A; Mann JF; Sleight P; Yusuf S; Teo KK;
Clin J Am Soc Nephrol; 2013 Feb; 8(2):233-40. PubMed ID: 23184565
[TBL] [Abstract][Full Text] [Related]
2. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
Clase CM; Barzilay J; Gao P; Smyth A; Schmieder RE; Tobe S; Teo KK; Yusuf S; Mann JF
Kidney Int; 2017 Mar; 91(3):683-690. PubMed ID: 27927602
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
[TBL] [Abstract][Full Text] [Related]
4. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
[TBL] [Abstract][Full Text] [Related]
5. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
[TBL] [Abstract][Full Text] [Related]
6. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
[TBL] [Abstract][Full Text] [Related]
7. Effect of telmisartan on renal outcomes: a randomized trial.
Mann JF; Schmieder RE; Dyal L; McQueen MJ; Schumacher H; Pogue J; Wang X; Probstfield JL; Avezum A; Cardona-Munoz E; Dagenais GR; Diaz R; Fodor G; Maillon JM; Rydén L; Yu CM; Teo KK; Yusuf S;
Ann Intern Med; 2009 Jul; 151(1):1-10, W1-2. PubMed ID: 19451556
[TBL] [Abstract][Full Text] [Related]
8. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
[TBL] [Abstract][Full Text] [Related]
9. Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk.
Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Emrich I; Mancia G; Redon J; Schmieder RE; Sliwa K; Lehrke M; Marx N; Weber MA; Williams B; Yusuf S; Mann JFE
J Hypertens; 2021 Apr; 39(4):766-774. PubMed ID: 33560052
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin blockade in late autosomal dominant polycystic kidney disease.
Torres VE; Abebe KZ; Chapman AB; Schrier RW; Braun WE; Steinman TI; Winklhofer FT; Brosnahan G; Czarnecki PG; Hogan MC; Miskulin DC; Rahbari-Oskoui FF; Grantham JJ; Harris PC; Flessner MF; Moore CG; Perrone RD;
N Engl J Med; 2014 Dec; 371(24):2267-76. PubMed ID: 25399731
[TBL] [Abstract][Full Text] [Related]
11. Renal protection in diabetes: lessons from ONTARGET.
Ritz E; Schmieder RE; Pollock CA
Cardiovasc Diabetol; 2010 Oct; 9():60. PubMed ID: 20920303
[TBL] [Abstract][Full Text] [Related]
12. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
Unger T
Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
[TBL] [Abstract][Full Text] [Related]
13. Albuminuria is associated with hip fracture risk in older adults: the cardiovascular health study.
Barzilay JI; Bůžková P; Chen Z; de Boer IH; Carbone L; Rassouli NN; Fink HA; Robbins JA
Osteoporos Int; 2013 Dec; 24(12):2993-3000. PubMed ID: 23702700
[TBL] [Abstract][Full Text] [Related]
14. Association of Increased Urinary Albumin With Risk of Incident Clinical Fracture and Rate of Hip Bone Loss: the Osteoporotic Fractures in Men Study.
Fink HA; Vo TN; Langsetmo L; Barzilay JI; Cauley JA; Schousboe JT; Orwoll ES; Canales MT; Ishani A; Lane NE; Ensrud KE
J Bone Miner Res; 2017 May; 32(5):1090-1099. PubMed ID: 28012217
[TBL] [Abstract][Full Text] [Related]
15. Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study.
Clase CM; Gao P; Tobe SW; McQueen MJ; Grosshennig A; Teo KK; Yusuf S; Mann JF;
Ann Intern Med; 2011 Mar; 154(5):310-8. PubMed ID: 21357908
[TBL] [Abstract][Full Text] [Related]
16. The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics.
Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL
Clin Res Cardiol; 2009 Jul; 98(7):421-33. PubMed ID: 19347385
[TBL] [Abstract][Full Text] [Related]
17. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.
Held C; Gerstein HC; Yusuf S; Zhao F; Hilbrich L; Anderson C; Sleight P; Teo K;
Circulation; 2007 Mar; 115(11):1371-5. PubMed ID: 17339550
[TBL] [Abstract][Full Text] [Related]
18. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes.
Schmieder RE; Delles C; Mimran A; Fauvel JP; Ruilope LM
Diabetes Care; 2007 Jun; 30(6):1351-6. PubMed ID: 17337492
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
Sharma A; Baliga V;
J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142
[TBL] [Abstract][Full Text] [Related]
20. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
Böhm M; Baumhäkel M; Teo K; Sleight P; Probstfield J; Gao P; Mann JF; Diaz R; Dagenais GR; Jennings GL; Liu L; Jansky P; Yusuf S;
Circulation; 2010 Mar; 121(12):1439-46. PubMed ID: 20231536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
